Article

Circulating tumor DNA: An alternative to tissue biopsy for detecting EGFR mutation in NSCLC

2025-09-21

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Non-small cell lung cancer (NSCLC) patients who have mutations in their EGFR gene respond more favorably to Tyrosine Kinase Inhibitors (TKIs) than to standard chemotherapy. However, tissue biopsy-based EGFR testing is invasive, costly, and technically challenging. Plasma-derived circulating tumor DNA (ctDNA) offers a minimally invasive and cost-efficient alternative for muta...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 28864ea8-abbc-5be4-a90c-761f7e85c895
DOI: 10.1101/2025.09.19.25336178

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Circulating tumor DNA: An alternative to tissue biopsy for detecting EGFR mutation in NSCLCDOI 10.1101/2025.09.19.25336178Read

CONCORDANCE: A real-world evidence study to evaluate the concordance of detecting epidermal growth factor receptor (EGFR) mutation by circulating tumor DNA* versus tissue biopsy in patients with metastatic non-small cell lung cancer.Semantic proximity Read

Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis.Semantic proximity Read

ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung CancerSemantic proximity Read

ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study.Semantic proximity Read

Liquid Biopsy for EGFR Mutation Detection in NSCLC: Evaluation of Plasma ctDNA and Comparison with Plasma exoDNA.Semantic proximity Read

The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer.Semantic proximity Read

Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs.Semantic proximity Read

Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer.Semantic proximity Read

Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancerSemantic proximity Read

Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction.Semantic proximity Read

Concordance of ctDNA and tissue mutations in NSCLC: A meta-analysis.Semantic proximity Read

Plasma ctDNA increases tissue NGS-based detection of therapeutically targetable mutations in lung cancers.Semantic proximity Read